Abstract:BACKGROUND:Neoadjuvant chemotherapy followed by cytoreduction surgery has been used where an accurate cytologic or pathologic diagnosis is usually required before the initiation of neoadjuvant chemotherapy. However, it is difficult to make definitive diagnosis of presence of cancer cells, particularly gynecologic versus non-gynecologic origin, from those ascites specimens due to the absence of specific biomarkers of gynecologic cancers. In the present study, we evaluated if, in addition to the routine morphologic diagnosis, the biomarker PAX8 could be useful in recognition of ovarian epithelial cancer cells prior to the neoadjuvant chemotherapy.METHODS:Two hundred and two cytology specimens including 120 pretreatment ovarian cancer samples, 60 benign controls, and 22 malignant non-gynecologic cases were studied. All cytology slides were morphologically reviewed in a blinded fashion without knowing corresponding pathology diagnosis, if present. A total of 168 cytology specimens with a cell block were stained with PAX8 and Calretinin. These included patients with potential for ovarian cancer neoadjuvant chemotherapy (n=96), metastatic cancers (n=22), and benign controls (n=50).RESULTS:Among the 96 ascitic samples prior to neoadjuvant chemotherapy, 76 (79%) showing morphologic features consistent with cancers of ovarian primary were all PAX+/Calretinin-. The remaining 20 (21%) cases were positive for adenocarcinoma, but morphologically unable to be further classified. Among the 22 metastatic cancers into the pelvis, one case with PAX8+/Calretinin- represented a renal cell carcinoma and the remaining 21 PAX8-/Calretinin- metastatic cancers were either breast metastasis (n=4) and the metastasis from gastrointestinal tract (n=17). Among the 50 benign control pelvic washing cases, 5 PAX8+/Calretinin-cases represented endosalpingiosis (n=4) and endometriosis (n=1), 25 PAX8-/Calretinin+cases showed reactive mesothelial cells, and the remaining 20 specimens with PAX8-/Calretinin- phenotype typically contained inflammatory or blood cells without noticeable diagnostic epithelia.CONCLUSIONS:PAX8 identifies all Müllerian derived benign or malignant epithelia. When combining with Calretinin, PAX8 is a sensitive marker to diagnose the carcinomas of ovarian origin, which will be ideal to be used for those patients with a possible advanced ovarian cancer prior to receiving neoadjuvant chemotherapy.

PAX2 and PAX8 Reliably Distinguishes Ovarian Serous Tumors from Mucinous Tumors.

PAX8 is a Novel Marker for Differentiating Between Various Types of Tumor, Particularly Ovarian Epithelial Carcinomas

Expression of Octamer-4 in Serous and Mucinous Ovarian Carcinoma.

Pax8 Is A Novel Marker For Differentiating Between Various Types Of Tumor, Particularly Ovarian Epithelial Carcinomas (Review)

Expression of Sox2 in Human Ovarian Epithelial Carcinoma.

PAX8 is a Potential Marker for the Diagnosis of Primary Epithelial Ovarian Cancer

Immunohistochemical expression of SATB2 and PAX8 in differentiating primary from metastatic ovarian mucinous neoplasms

Clinical significance of PAX8 expression in ovarian malignant tumor lesions

Differentiating primary and extragenital metastatic mucinous ovarian tumours: an algorithm combining PAX8 with tumour size and laterality.

Podocalyxin-Like Protein 1 Expression and Correlation with Clinical Characteristics in Epithelial Serous and Mucinous Ovarian Carcinoma and Tumor-Like Lesions

Podocalyxin-like protein 1 expression and correlation with clinical characteristics in epithelial serous and mucinous ovarian carcinoma and tumor-like lesions.

PAX8: a Sensitive and Specific Marker to Identify Cancer Cells of Ovarian Origin for Patients Prior to Neoadjuvant Chemotherapy.

and laterality algorithm combining PAX 8 with tumour size metastatic mucinous ovarian tumours : an Differentiating primary and extragenital and

Expression of PAX8, Tubulin and Calretinin in ovarian mucinous tumors and clear cell cancer

Expression and Significance of PAX8 Gene in Ovarian Cancer Based on Oncomine Database Meta-analysis

Detection of PAX8 and P53 is Beneficial in Recognizing Metastatic Carcinomas in Pelvic Washings, Especially in Cases with Suspicious Cytology.

PAX8 expression in cancerous and non-neoplastic tissue: a tissue microarray study on more than 17,000 tumors from 149 different tumor entities

SOX17: A Highly Sensitive and Specific Immunomarker for Ovarian and Endometrial Carcinomas

UnPAXing the Divergent Roles of PAX2 and PAX8 in High-Grade Serous Ovarian Cancer

PAX2 Promotes Epithelial Ovarian Cancer Progression Involving Fatty Acid Metabolic Reprogramming

[Clinicopathologic Study and Immunohistochemistry Comparison of Pax2, P53 and Ki-67 in Low- and High-Grade Ovarian Serous Carcinomas].